Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer

Author(s):  
Olga T. Filippova ◽  
Amy L. Tin ◽  
Joanne Alonso ◽  
Andrew J. Vickers ◽  
William P. Tew ◽  
...  
Menopause ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Michelle R. Jacobson ◽  
Melissa Walker ◽  
Gabrielle E.V. Ene ◽  
Courtney Firestone ◽  
Marcus Q. Bernardini ◽  
...  

2014 ◽  
Vol 25 ◽  
pp. iv317
Author(s):  
L.H. Horsley ◽  
S. Booth ◽  
P. Potter ◽  
A. Clamp ◽  
G.C. Jayson ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA6009-CRA6009
Author(s):  
Joseph M Unger ◽  
Dawn L. Hershman ◽  
Kenda Burg ◽  
Carol Moinpour ◽  
Kathy S. Albain ◽  
...  

CRA6009 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News


2015 ◽  
Vol 11 (3) ◽  
pp. e267-e278 ◽  
Author(s):  
Kenneth L. Kehl ◽  
Mary Beth Landrum ◽  
Katherine L. Kahn ◽  
Stacy W. Gray ◽  
Aileen B. Chen ◽  
...  

Among patients with lung or colorectal cancer, frequent physician tumor board engagement was associated with patient clinical trial participation and higher rates of curative-intent surgery for stage I to II NSCLC but not with overall survival.


2009 ◽  
Vol 19 (1) ◽  
pp. 124-128 ◽  
Author(s):  
William R. Robinson ◽  
Joyce Ritter ◽  
April S. Rogers ◽  
Sean Tedjarati ◽  
Christy Lieberenz

Objectives:To determine the effect of participation in clinical trials on survival of women with ovarian cancer. Disease-specific factors and demographics were also examined.Methods:A total of 158 women were treated for ovarian cancer at a regional cancer center. All patients were offered treatment with surgery/chemotherapy and were screened at diagnosis for participation in clinical research. Progression-free and overall survival, as well as demographic- and treatment-related data, were recorded.Results:Fifty-three participated in clinical trials and 105 did not. On-study versus off-study subjects were similar in age (64.1 vs 63.5 years), ethnicity (87% vs 85% white), performance status (100% 0-1 Gynecologic Oncology Group scale), and urban versus rural lifestyle (58% vs 55% urban). Stage of disease, histologic subtype, and type/amount of therapy were also similar. Kaplan-Meier analysis showed superior overall survival for on-study subjects (median, 46 vs 25 months, 95% confidence interval, 1.0299-2.1505 months, P = 0.0343). A trend toward improved progression-free survival approached significance for on-study subjects (median, 23 vs 9 months, 95% confidence interval, 0.9545-2.0022 months, P = 0.0866).Conclusions:Women with ovarian cancer who participate in clinical trials at this institution have improved survival compared with those who are treated with standard therapies. No other factors examined were associated with treatment completion or survival. Further, participation in clinical research does not vary by age, ethnicity, urban versus rural lifestyle, or cancer stage or histologic subtype. However, disclosure of this information to potential clinical trial participants may represent an ethical conflict and should be carefully considered in light of existing ethical guidelines for human subject research.


Sign in / Sign up

Export Citation Format

Share Document